.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
McKesson
Cipla
Fuji
Express Scripts
QuintilesIMS
Covington
Novartis
Deloitte
Chubb

Generated: February 25, 2018

DrugPatentWatch Database Preview

US Patents With Foreign Priority to Denmark Patent: 2003 01129

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novo Nordisk IncRYZODEG 70/30insulin aspart; insulin degludecSOLUTION;SUBCUTANEOUS203313-001Sep 25, 2015RXYesYes➤ Sign Up➤ Sign UpYY
Novo Nordisk IncTRESIBAinsulin degludecSOLUTION;SUBCUTANEOUS203314-001Sep 25, 2015RXYesNo➤ Sign Up➤ Sign UpYY
Novo Nordisk IncTRESIBAinsulin degludecSOLUTION;SUBCUTANEOUS203314-002Sep 25, 2015RXYesYes➤ Sign Up➤ Sign UpYY
Novo Nordisk IncXULTOPHY 100/3.6insulin degludec; liraglutideSOLUTION;SUBCUTANEOUS208583-001Nov 21, 2016RXYesYes➤ Sign Up➤ Sign UpYY
This preview shows a limited number of results
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist